jueves, 1 de agosto de 2019

In-hospital mortality associated with the misdiagnosis or unidentified site of infection at admission. | AHRQ Patient Safety Network

In-hospital mortality associated with the misdiagnosis or unidentified site of infection at admission. | AHRQ Patient Safety Network

PSNet email header



  • Review
  •  
  • Published June 2019

In-hospital mortality associated with the misdiagnosis or unidentified site of infection at admission.

    This retrospective study sought to determine whether timely diagnosis of the site of infection affected in-hospital mortality for sepsis. Investigators found that patients whose infection site was misdiagnosed on admission had more than twofold greater odds of dying in the hospital compared to those with the correct infection site diagnosed on admission. These results reinforce the importance of correct and timely diagnosis for sepsis outcomes.






    View More

    Medication safety alert fatigue may be reduced via interaction design and clinical role tailoring: a systematic review. | AHRQ Patient Safety Network

    Medication safety alert fatigue may be reduced via interaction design and clinical role tailoring: a systematic review. | AHRQ Patient Safety Network

    PSNet email header

    • Review
    •  
    • Published June 2019

    Medication safety alert fatigue may be reduced via interaction design and clinical role tailoring: a systematic review.

      This systematic review examined the override rates of several different clinical decision support approaches. Researchers conclude that role tailoring—the provision of different alerts to prescribers versus pharmacists—was the most successful method to reduce alert fatigue. They recommend redesigning decision support to reduce alert fatigue.










      View More

      Study of a multisite prospective adverse event surveillance system. | AHRQ Patient Safety Network

      Study of a multisite prospective adverse event surveillance system. | AHRQ Patient Safety Network

      PSNet email header

      • Study
      •  
      • Published July 2019

      Study of a multisite prospective adverse event surveillance system.

        This prospective study used a trigger tool approach to identify potential adverse events among hospitalized patients in real time. Researchers found widely varying adverse rates among the five hospitals and concluded that event detection among the trigger event reviewers was responsible for some of the variation in observed events. These results underscore the challenge of accurate adverse event surveillance.








        View More

        Duration of second victim symptoms in the aftermath of a patient safety incident and association with the level of patient harm: a cross-sectional study in the Netherlands. | AHRQ Patient Safety Network

        Duration of second victim symptoms in the aftermath of a patient safety incident and association with the level of patient harm: a cross-sectional study in the Netherlands. | AHRQ Patient Safety Network

        PSNet email header



        • Study
        •  
        • Published July 2019

        Duration of second victim symptoms in the aftermath of a patient safety incident and association with the level of patient harm: a cross-sectional study in the Netherlands.

          Clinicians may experience distress after being involved in adverse events. This study of 4369 Dutch providers examined the prevalence and duration of clinicians' symptoms associated with involvement in an adverse event as well as the relationship between the degree of harm and symptom duration. As expected, clinicians reported symptoms such as hypervigilance, self-doubt, and discomfort following adverse events. These symptoms were more severe and long lasting for events with more serious harm to patients, compared to events with less severe harm. The authors call for organizations to provide support for clinicians involved in adverse events. A previous PSNet perspective discussed efforts to ameliorate the impact of errors on providers.




          View More

          Prevalence, severity, and nature of preventable patient harm across medical care settings: systematic review and meta-analysis. | AHRQ Patient Safety Network

          Prevalence, severity, and nature of preventable patient harm across medical care settings: systematic review and meta-analysis. | AHRQ Patient Safety Network

          PSNet email header

          • Study
          •  
          • Published July 2019

          Prevalence, severity, and nature of preventable patient harm across medical care settings: systematic review and meta-analysis.

            The extent of harm due to patient safety problems varies across studies. This systematic review sought to estimate the prevalence of preventable harm in medical care overall. Researchers synthesized data from 70 studies and estimated that 6% of patients receiving medical care experience preventable harm. Harm related to medicationsdiagnosishealth care–associated infections, and procedures accounted for significant proportions of preventable harm. The authors conclude that focusing on evidenced-based strategies to address preventable patient harm would improve health care quality and subsequently reduce costs. A related editorial calls for improving measurement of preventable harm. Another editorial spotlights the importance of understanding the causes of preventable harm in health care.






            View More

            Explained: What’s at stake in India’s biggest ever trial of tuberculosis vaccines | Explained News, The Indian Express

            Explained: What’s at stake in India’s biggest ever trial of tuberculosis vaccines | Explained News, The Indian Express
            Written by Anuradha Mascarenhas |Pune |Updated: August 1, 2019 6:56:59 am

            Explained: What’s at stake in India’s biggest ever trial of tuberculosis vaccines

            Treating TB requires a multi-drug course of treatment lasting six months; longer still for treating drug-resistant TB. Treatment failure and recurrence can have devastating consequences.


            icmr new tuberculosis vaccines, Indian Council of Medical Research, ICMR new tb vaccines, tb vaccines,
            India contributes to 27 per cent of the global TB burden; the highest share globally. (Source: File Photo)

            On July 15, the Indian Council of Medical Research (ICMR) launched India’s first large-scale trial for two new tuberculosis (TB) vaccines.